These findings establish EXO1 inhibitorsas promising candidates for the treatment of HRD cancers and lay thegroundwork for the further optimization and development of these compoundsas targeted therapeutics. Here, EXO1 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.